



ASX / MEDIA RELEASE

16th May 2016

Appointment of Kevin Richardson to CEO of the Americas Region

Sydney, Australia; 16th May 2016 – Sirtex Medical (ASX:SRX) today announces that Mr Kevin Richardson has been appointed to the role of Chief Executive Officer, Americas effective from 1st July, 2016. Kevin currently serves as the General Manager and Vice President for North America at Sirtex Medical, a role he has held for the past six years. He is also a Member of the US Executive Committee.

Kevin brings both significant and direct senior management and leadership experience to the Americas business, having been responsible for overall sales, market development, customer service and health economics at Sirtex Medical. Prior to joining Sirtex Medical, Kevin held Senior Director roles in Sales and Marketing at St. Jude Medical and was a Global Marketing Director at Boston Scientific.

Mr Gilman Wong, Chief Executive Officer of Sirtex Medical commented “We are delighted Kevin has accepted the CEO role for our important Americas region. We conducted a very thorough and comprehensive executive search process that identified a number of high calibre external and internal candidates. However, with over 20 years of medical device experience gained at both Sirtex and at other large device companies, coupled with his strong people and leadership skills, Kevin was a standout candidate for the role. I am very confident that with Kevin’s strategic approach to our business and under his organisational leadership, the Americas will continue to be a very important growth region for Sirtex Medical moving forward.”

About SIR-Spheres[®] Y-90 Resin Microspheres

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered via Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, directly to liver tumours. SIR-Spheres Y-90 resin microspheres are approved for supply in key markets, such as the United States, European Union and Australia.

About Sirtex Medical

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. Approximately 61,000 doses have been supplied to treat patients with liver cancer at more than 950 medical centres in over 40 countries. For more information please visit www.sirtex.com.

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406

For further information please contact:

Investor Enquiries:

Mr Gilman Wong
CEO
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

Media Enquiries:

Tim Allerton or Andrew Geddes
City PR
Phone: +61 (0) 2 9267 4511

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd